Candida albicans is a common human fungal pathogen that colonizes mucosa and develops bio lm in the oral cavity which cause oral candidiosis. This study investigates the effects of a new molecule thidiazuron against the growth and bio lm formation properties of C. albicans. Preliminary molecular docking study revealed potential interaction between thidiazuron and amino acids residues of cytochrome P450 mono-oxygenase (CYP51). Further in vitro anti-fungal susceptibility test, scanning electron microscopy (SEM) and time kill analysis revealed potential anti-fungal activity of thidiazuron in both dose and time dependent manner. Crystal violet staining, 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) reduction assay and acridine orange staining visually con rmed bio lm inhibitory potential of thidiazuron. Gene expression study shows that thidiazuron treatment down regulated the expression of genes involved in ergosterol synthesis, cell adhesion and hyphae development in C. albicans. This study identi ed thidiazuron as a new CYP51 inhibitor and a novel antibio lm agent against C. albicans.